Mirvetuximab Soravtansine Given FDA Fast Track Designation for Ovarian Cancer Treatment

Mirvetuximab Soravtansine Given FDA Fast Track Designation for Ovarian Cancer Treatment
Mirvetuximab soravtansine (IMGN853), an investigational antibody-drug conjugate, has been granted fast track designation by the U.S. Food and Drug Administration for the treatment of ovarian cancer patients, ImmunoGen, the therapy’s maker, announced. The designation is for the treatment of ovarian cancer patients positive for folate receptor alpha (FRα), who aren’t responding to platinum-based chemotherapy, and for whom single-agent

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *